it recently made an unsolicited $29 billion bid for parago. people familiar with the matter of greece say the ecb may reduce the amount that could be borrowed for collateral. this is happening while europe waits to see greece will agree to a new package of economic reforms in return for more bill money. in an interview with bloomberg one says no one is optimistic about greece right now. >> we have to be totally realistic. it all depends on the maturing of the position of the greek government understanding that in any case if it wants to deliver growth and jobs which is the main goal of that government, it has to produce recovery program. erik: he says he hasn't heard any european finance ministers are just greece should abandon the euro. the ride sharing service u ber now has a deal with a major critic or company. capital one card called holders will get a percentage of their uber receipt return. the largest u.s. wireless carrier reported for scored a profit that beat estimates but nevertheless verizon had to give away tablets and offer deep d

then milan, this afternoon, announcing it was offering to parago to buy it for $28.6 billion. nearly $30 billion deal. jackie deangeles covering the energy deal. first, though to meg terrell who is here at hq on this breaking announcement in the middle of the afternoon. >> it was kind of unusual coming out right in the middle of the trading day that milan is offering to buy parago for $205 a share. almost $30 billion in a combination of cash and stock. mylan saying that represents 25% where perrigo was at earlier this week. in a public letter the twol companies have had a number of discussions over the last few years, and this deal would give both more scale and reach in an environment where those are increasingly important. the combination would create a company with more than $15 billion in annual revenue, he says, from generic and over-the-counter medicines. both companies stocks are trading that they're surpassing. they're now trading about $200. the deal comes amid an unprecedented flurry of consolidation in the drug industry. much of it of course driven by tax considerat

talk to parago, we're doing we can. hane a blank check.ld days organic and natural they sent you to rice krispy bars. >> it's interesting, mcmillan does seem to be doing any number of important things and it would seem you were down not long ago on the important wage decision they made. >> now speaking up on this arkansas bill asking governor to veto it saying it violates the spirit of inclusion. we asked him to come on air and talk about it today. that's not going to happen. i mean it's surprised some people a company of that size said don't do this. >> i think a at of people -- this is a hot button -- i'm going to refer you to a new york time stories says these are not the same as 1992. those are about government intrusion in people's lives. this business corporate, corporate trade-offs where a corporation, small corporation, can say no to you to do business. >> the supreme court's decision in the hobby lobby case which did give power to corporations to say, we're not going to do that. >> let's just open hand a lot of people feel that th

parago's trading below the offer price.o perrigo, in talking to people familiar with the situation, did not expect this to show up at their doorstep this proposal. it was unexpected. they're going to take their time. don't expect we'll get some sort of resolution here in any near term. the indications i'm getting, they're going to take time and reviewing the offer. they have morgan stanley working at perrigo. so we'll see what they choose to do and what mylan chooses to do and what teva chooses to do. but nobody argues what the strategic logic of potential deal. when you think about a teva/mylan, israel and west virginia getting together -- no offense to either one please -- but culturally that could be interesting. >> read the book a novel came out in '70s, texas/israeli war. >> no. >> unbelievably bad. i do think -- >> my brother-in-law gave it to me. i do think that the fact that you mentioned the key words, specialty pharma. when this thing's over there's going to be like three specialty pharma companies. now watch this